[Abstract Only] Randomized Trial: Anti-CD19 Monoclonal Antibody Tested for the Treatment of Neuromyelitis Optica Spectrum Disorder
15 Oct, 2019 | 08:29h | UTCInebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Anti-CD19 MAb Trial Halted Early for Benefit in NMO – Medscape (free registration required)